New Zealand regulations logical and flexible. Biological border surveillance means likelihood of unwanted disease entering New Zealand is extremely low. This biosecurity effort is critical to the industry. New Zealand biotechnology sector has a substantial volume of export business and operates in many overseas markets. Growth is more rapid in the plant, marine and synthetic areas than in animal products due to the threat of animal diseases.
Biotechnology plays a key role in waste treatment and remediation.
Owing to the high growth in the biotechnology industry, education is emphasised. Outcomes Vigilant MAF border control and increased support for the control of annual pests and diseases. Regulations to restrict the exportation of native terrestrial and marine flora and fauna need to be introduced unless the appropriate intellectual security and ownership issues are clear. A review of regulatory requirements conducted and greater industry input into developing the regulatory environment. Resolving Waitangi Claim 262 speeded up with an outcome that allows the commercial use of biological materials from indigenous species.